Product image of Jansitin (Sitagliptin) supplied by GNH India

Jansitin

Active Ingredient:
Sitagliptin
Origin:
EU

Jansitin (Sitagliptin)

Sitagliptin, the active ingredient in Jansitin, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, where it enhances glucose‑dependent insulin secretion and reduces post‑prandial glucose excursions, supporting overall glycemic control.

GNH India supplies Jansitin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, quality assurance and regulatory support for global distribution. The company adheres to EU standards and ensures timely delivery to diverse markets.

Manufacturer / TM Owner

G.L. Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Sitagliptin is used in the management of type 2 diabetes, acting on the incretin pathway to improve glycemic control.

  • Type 2 diabetes mellitus: improves blood glucose levels when combined with diet and exercise.
  • Adjunct therapy for type 2 diabetes: enhances insulin secretion in patients inadequately controlled on metformin.
  • Combination therapy with other antidiabetic agents: provides additional HbA1c reduction alongside sulfonylureas or insulin.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which degrades the incretin hormones glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). By blocking DPP‑4, sitagliptin increases circulating levels of GLP‑1 and GIP, enhancing glucose‑dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying, thereby improving post‑prandial and overall glycemic control.

Side Effects

Sitagliptin may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Nausea: mild gastrointestinal upset occurring in some patients.
  • Headache: transient head discomfort reported during treatment.
  • Nasopharyngitis: upper respiratory tract infection symptoms such as sore throat or runny nose.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with elevated enzymes requiring immediate medical attention.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Joint pain: unexplained arthralgia that may be persistent.

Precautions & Warnings

When prescribing sitagliptin, clinicians should consider several safety considerations to minimize risk.

  • Renal function: assess baseline kidney function and adjust use in moderate to severe impairment.
  • Hypoglycemia risk: monitor blood glucose closely if combined with insulin or sulfonylureas.
  • Cardiovascular disease: use with caution in patients with a history of heart failure.
  • Elderly patients: consider initiating at a lower dose due to potential decreased clearance.
  • Pregnancy and lactation: safety not established; avoid unless benefits outweigh potential risks.
  • Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Avoid Interactions

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Insulin: concurrent use may increase risk of hypoglycemia.
  • Sulfonylureas: combined therapy can potentiate low blood glucose episodes.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma concentrations.

Moderate Interactions (Monitor Closely)

  • Diuretics: monitor renal function as changes may affect sitagliptin clearance.
  • Rifampin: may reduce sitagliptin exposure, potentially diminishing glycemic effect.

Frequently Asked Questions

Jansitin contains sitagliptin, which is prescribed for the treatment of type 2 diabetes mellitus. It helps lower elevated blood glucose by enhancing the body’s own insulin response after meals and improving overall glycemic control when used together with diet and exercise.

Sitagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises the levels of the incretin hormones GLP‑1 and GIP, which stimulate insulin release and suppress glucagon when glucose is present, thereby reducing blood sugar levels.

The appropriate dose of Jansitin is determined by the prescribing healthcare professional based on the individual’s medical condition, renal function, and response to therapy. Patients should follow the exact dosing instructions provided by their prescriber and not adjust the dose on their own.

Safety of sitagliptin in pregnancy and lactation has not been firmly established. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Jansitin, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas or insulin, sitagliptin offers glucose‑dependent insulin secretion without causing weight gain and has a lower risk of hypoglycemia when used alone. It is often added to metformin or other agents to achieve additional HbA1c reduction, providing a convenient oral option.

Jansitin should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and discard any tablets that appear discolored or damaged.

Jansitin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients must follow the dosing schedule prescribed by their healthcare professional.

The most serious adverse events associated with sitagliptin include pancreatitis, severe allergic reactions such as anaphylaxis, and persistent joint pain. Patients should seek immediate medical attention if they experience severe abdominal pain, rash with swelling, or unexplained arthralgia.

Jansitin is contraindicated in individuals with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for patients with severe renal impairment, a history of pancreatitis, or those who are pregnant or breastfeeding unless clearly indicated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT